{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:01:37Z","timestamp":1792519297148,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019476","name":"Siriraj Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omton.2024.200889","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T03:22:03Z","timestamp":1728098523000},"page":"200889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1639-4935","authenticated-orcid":false,"given":"Sudjit","family":"Luanpitpong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phatchanat","family":"Klaihmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montira","family":"Janan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Kungwankiattichai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chutima","family":"Kunacheewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supasorn","family":"Chanthateyanonth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawapotch","family":"Donsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowalak","family":"U-pratya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanatphak","family":"Warindpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janejira","family":"Kittivorapart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parichart","family":"Permpikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surapol","family":"Issaragrisil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200889_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: Focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev."},{"key":"10.1016\/j.omton.2024.200889_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front. Transplant."},{"key":"10.1016\/j.omton.2024.200889_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2024.200889_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1024362","article-title":"Impact of cryopreservation on CAR T production and clinical response","volume":"12","author":"Brezinger-Dayan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2024.200889_bib5","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","article-title":"Effect of cryopreservation on autologous chimeric antigen receptor T\u00a0cell characteristics","volume":"27","author":"Panch","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200889_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T\u00a0cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2024.200889_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T\u00a0cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2024.200889_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T\u00a0cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.omton.2024.200889_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.56875\/2589-0646.1048","article-title":"Chimeric antigen receptor structure and manufacturing of clinical grade CAR engineered cells using different bioreactors","volume":"15","author":"Syed","year":"2022","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.omton.2024.200889_bib10","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.2147\/DDDT.S175113","article-title":"Characterization of clinical grade CD19 chimeric antigen receptor T\u00a0cells produced using automated CliniMACS Prodigy system","volume":"12","author":"Zhang","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omton.2024.200889_bib11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00262-018-2155-7","article-title":"Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T\u00a0cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia","volume":"67","author":"Blaeschke","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200889_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cgt.2014.71","article-title":"Manufacturing genetically modified T\u00a0cells for clinical trials","volume":"22","author":"Gee","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2024.200889_bib13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.eng.2018.12.003","article-title":"Quality control and nonclinical research on CAR-T cell products: general principles and key issues","volume":"5","author":"Li","year":"2019","journal-title":"Engineering"},{"key":"10.1016\/j.omton.2024.200889_bib14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.omton.2024.200889_bib15","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.3390\/cells10113208","article-title":"Sensitivity and specificity of CD19.CAR-T cell detection by flow cytometry and PCR","volume":"10","author":"Schanda","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omton.2024.200889_bib16","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/j.jcyt.2020.03.283","article-title":"Vector copy number quality control testing for CAR T-cells: critical validation parameters","volume":"22","author":"Chen","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2024.200889_bib17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3389\/fimmu.2020.01217","article-title":"Next-generation manufacturing protocols enriching TSCM CAR T\u00a0cells can overcome disease-specific T\u00a0cell defects in cancer patients","volume":"11","author":"Arcangeli","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200889_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40164-020-00190-2","article-title":"Engineering better chimeric antigen receptor T\u00a0cells","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.omton.2024.200889_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3389\/fimmu.2020.00482","article-title":"Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: Experience from an academic phase I clinical trial","volume":"11","author":"Castella","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200889_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T\u00a0cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200889_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200889_bib22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.omton.2024.200889_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200889_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjh.18831","article-title":"Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan","volume":"202","author":"Jo","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2024.200889_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T\u00a0cells using the CliniMACS Prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2024.200889_bib26","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200889_bib27","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","article-title":"Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients","volume":"12","author":"Maschan","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200889_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200889_bib29","doi-asserted-by":"crossref","first-page":"7474","DOI":"10.1182\/blood-2022-167340","volume":"140","author":"Vasu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2024.200889_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.omtm.2018.11.010","article-title":"Development of a novel anti-CD19 chimeric antigen receptor: A paradigm for an affordable CAR T\u00a0cell production at academic institutions","volume":"12","author":"Castella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2024.200889_bib31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2020.09.027","article-title":"CART19-BE-01: A multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed\/refractory malignancies","volume":"29","author":"Ort\u00edz-Maldonado","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2024.200889_bib32","article-title":"Factors associated with the clinical outcome of patients with relapsed\/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy","volume":"9","author":"Ortiz-Maldonado","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200889_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: How to improve their persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200889_bib34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omton.2024.200889_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.09.001","article-title":"Detection of replication competent lentivirus using a qPCR assay for VSV-G","volume":"8","author":"Skrdlant","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924001310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924001310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:00:00Z","timestamp":1734624000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924001310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2950329924001310"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200889","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200889"}}